Market Access/ News/ News Alnylam gets NICE backing for porphyria therapy Givlaari Phil Taylor Alnylam, Givlaari, HEOR, NICE, porphyria, rare disease 0 Comment UK cost-effectiveness watchdog NICE is set to recommend NHS use of Alnylam’s gene-silencing therapy Givlaari in England and Share X Alnylam gets NICE backing for porphyria therapy Givlaari https://pharmaphorum.com/news/alnylam-gets-nice-backing-for-porphyria-therapy-givlaari/
News FDA approves Alnylam’s second RNAi drug – with $442K annual price tag Richard Staines Alnylam, fda, porphyria 0 Comment Alnylam has had a second RNA interference (RNAi) drug approved by the FDA, to treat the ultra-rare disease Share X FDA approves Alnylam’s second RNAi drug – with $442K annual price tag https://pharmaphorum.com/news/fda-approved-alnylams-second-rnai-drug/
News/ News/ R&D Alnylam to file gene-silencing porphyria drug Richard Staines Alnylam, porphyria, Rare diseases 0 Comment Alnylam is to file its givosiran with regulators to treat a form of the blood disease porphyria, applying Share X Alnylam to file gene-silencing porphyria drug https://pharmaphorum.com/news/alnylam-to-file-gene-silencing-porphyria-drug/
Alnylam, Givlaari, HEOR, NICE, porphyria, rare disease
0 Comment
